PatentVest Report on Obesity Drug IP
Analysis based on 6 articles · First reported May 08, 2026 · Last updated May 08, 2026
The release of PatentVest's report on the triple-agonist obesity drug market is expected to increase investor attention on pharmaceutical and biotechnology companies involved in this space, particularly Eli Lilly and Company due to its leading candidate retatrutide. The report highlights the growing importance of intellectual property and delivery systems, which could influence investment strategies and valuations for companies like Novo Nordisk, Pfizer, Roche, and Sanofi, as well as emerging players.
PatentVest, a division of MDB Capital Holdings, released a comprehensive report titled 'The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market' on May 8, 2026. The report analyzes the rapidly evolving obesity drug landscape, focusing on the transition beyond first-generation GLP-1 therapies to triple-agonist programs. It highlights Eli Lilly and Company's retatrutide as a leading candidate and emphasizes that future competition will be driven by intellectual property positioning, delivery systems, and long-term market control, not just clinical outcomes. The study identifies 27 triple-agonist programs globally, with China playing a significant role in development. Key players include Eli Lilly and Company, Novo Nordisk, Pfizer, Roche, and Sanofi, alongside emerging biotechs like Hanmi Pharm, Innovent Biologics, Zealand Pharma, Septerna, Kailera Therapeutics, Metsera, Ascletis Pharma, Knight Therapeutics, Structure Therapeutics, and Viking Therapeutics. Will Rosellini, Chief IP Officer at PatentVest, stated that the next phase of obesity drug development will be defined by control over intellectual property, delivery platforms, and receptor configurations.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard